T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder, in which multiple genetic abnormalities cooperate in the malignant transformation of thymocytes. About 20% of pediatric T-ALL cases are characterized by TLX3 expression due to a cryptic translocation t(5;14)(q35;q32). Although a number of collaborating genetic events have been identified in TLX3 rearranged T-ALL patients (NOTCH1 mutations, p15/p16 deletions, NUP214-ABL1 amplifications), further elucidation of additional genetic lesions could provide a better understanding of the pathogenesis of this specific T-ALL subtype. In this study, we used array-CGH to screen TLX3 rearranged T-ALL patients for new chromosomal imbalances. Array-CGH analysis revealed five recurrent genomic deletions in TLX3 rearranged T-ALL, including del(1)(p36.31), del(5)(q35), del(13)(q14.3), del(16)(q22.1) and del (19)(p13.2). From these, the cryptic deletion, del(5)(q35), was exclusively identified in about 25% of TLX3 rearranged T-ALL cases. In addition, 19 other genetic lesions were detected once in TLX3 rearranged T-ALL cases, including a cryptic WT1 deletion and a deletion covering the FBXW7 gene, an U3-ubiquitin ligase that mediates the degradation of NOTCH1, MYC, JUN and CyclinE. This study provides a genome-wide overview of copy number changes in TLX3 rearranged T-ALL and offers great new challenges for the identification of new target genes that may play a role in the pathogenesis of T-ALL.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disorder of T-cells, and represents about 15% of pediatric ALL cases. T-ALL is characterized by a rapid progression of disease and shows a 30% relapse rate. 1 Over the last decade, a large number of new genomic aberrations were identified in T-ALL, including chromosomal translocations (involving the genes TAL1, LYL1, LMO1, LMO2, TLX1/HOX11, TLX3/ HOX11L2, MYB, Cyclin D2), deletions (SIL-TAL1, del(6q), del(9)(p21), del(11)(p12p13)), amplifications (NUP214-ABL1), duplications (MYB) and mutations (RAS, NOTCH1).
2-11 Several of these abnormalities represent unique and mutually exclusive aberrations possibly delineating distinct T-ALL subgroups. Others occur in combination with various of these subgroups, for example, the del(9)(p21) that includes the CDKN2A/p15 and CDKN2B/p16 loci both deregulating the cell cycle. 3, 12 Also NOTCH1 activation mutations are present in more than half of all T-ALL cases of all subgroups. 9 The genetic defects as identified in T-ALL so far target different cellular processes, including cell cycle regulation, T-cell differentiation, proliferation and survival. It is hypothesized that these genetic events cooperate in the leukemic transformation of thymocytes.
13
TLX3 is a homeobox gene that is not expressed in normal T-cell development. In T-ALL patients, it becomes aberrantly activated due to the cryptic translocation, t(5;14)(q35;q32), mostly juxtaposing TLX3 to the BCL11B gene. BCL11B is normally expressed during T-cell maturation.
14 Some alternative TLX3 translocations have been described including the t(5;14) (q32;q11) juxtaposing TLX3 to the TCRa/d locus, 15 and the t(5;7)(q35;q21) coupling TLX3 to the CDK6 gene. 16 Although there is a clear relationship between the presence of TLX3 translocations and TLX3 expression levels, 17 incidental TLX3 expression has been described in the absence of chromosomal abnormalities, 18, 19 suggesting that alternative mechanisms for TLX3 activation exist in T-ALL. Conflicting data have been published about the relation between TLX3 expression and treatment outcome. In some studies, TLX3 rearranged T-ALL patients showed a poor prognosis, whereas in other studies TLX3 translocations had no effect on outcome or was even associated with an improved outcome. 17, 20, 21 These discrepancies have not been clarified thus far, but may be therapy-dependent.
In this study, we used microarray-based comparative genome hybridization (array-CGH) to screen TLX3 rearranged pediatric T-ALL patients for new chromosomal imbalances that could provide further insight in the development of TLX3-mediated T-cell leukemia.
Design and methods

Patients
Viably frozen diagnostic bone marrow or peripheral blood samples from 146 pediatric T-ALL patients were provided by the Dutch Childhood Oncology Group and the German Co-operative Study Group for childhood acute lymphoblastic leukemia. 17 The patients and patients' parents or their legal guardians provided informed consent to use leftover material for research purposes. Leukemic cells were isolated and enriched from these samples as previously described, 8 and genomic DNA and total cellular RNA were isolated as described before. 8 Quantitative real-time RT-PCR (RQ-PCR). cDNA synthesis and RQ-PCR in an ABI 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) was used to quantify the expression levels of TLX3 transcripts relative to the endogenous housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as described previously.
17 NUP214-ABL1 fusions were determined as previously described. 4 
Oligo array-CGH
Oligo array-CGH analysis was performed on the human genome CGH Microarray 44A (Agilent Technologies, Palo Alto, CA, USA) according to the manufacturer's protocol, as previously described. 8 Microarray images were analyzed using feature extraction software (version 8.1, Agilent) and the data were subsequently imported into array-CGH analytics software v3.1.28 (Agilent). For the detection of copy number abnormalities, we have used a Z-score cutoff value of 3. All copy number aberrations were compared to the database of genomic variants (http://projects.tcag.ca/variation) and all genomic regions previously linked to copy number variations 22 were not included in Table 1 .
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed using a standard procedure, as described previously.
17 TLX3 translocations were determined using the TLX3-U/TLX3-D translocation probes (DakoCytomation, Glostrup, Denmark). BAC probes RP11-299P16 and RP11-98C11 (BACPAC resources, Oakland, CA, USA) were used to confirm the presence of Wilms' tumor 1 (WT1) deletions, whereas RP11-300I24 and RP11-650G8 were used to confirm the FBXW7 deletion. RP11-1072I20 (RANBP17/ TLX3), RP11-10N18 (RANBP17) and RP11-117L6 (downstream of TLX3) as well as CTD-2243O22 (5qter) (Invitrogen, Breda, the Netherlands) were used to further characterize the deletion, del(5)(q35).
Real-time quantification of DNA copy number
Deletion analysis was performed using real-time quantitative PCR of the NSD1 gene relative to the internal control gene, albumin, as previously described. 23 
Mutation analysis
For the detection of WT1 mutations, the purified DNA was subjected to 40 0 -CTGCACCACTGAGAACAAG-3 0 for exon 12, using similar PCR conditions as described above. NOTCH1 mutation screening in T-ALL was performed as previously described. 24 PCR products were purified by standard methods and directly sequenced from both strands. The sequence data were analyzed using Seqscape V2.5 (Applied Biosystems). Genetic lesions in TLX3 pediatric T-ALL P Van Vlierberghe et al
Results
Collaborating genetic events in TLX3 rearranged T-ALL
In our previous study, we screened a large pediatric T-ALL cohort (n ¼ 146) for TLX3 rearrangements using FISH and identified 29 of 146 (19%) rearranged cases, 17 in line with previous studies. 18, 19 All TLX3 rearranged cases uniquely expressed TLX3 whereas other T-ALL cases were negative. 17 To identify additional genetic abnormalities that may cooperate with TLX3 expression during T-cell leukemogenesis, we performed array-CGH analysis to detect genomic amplifications or deletions on those TLX3 rearranged T-ALL cases for which material was available (n ¼ 21). All genomic deletions and/or amplifications as identified by array-CGH are summarized in Table 1 , except for known polymorphic copy number variations. 22 Genomic deletions are more abundant as compared to amplifications, as only two regions of genomic amplification in contrast to 22 regions of genomic deletion were identified in our TLX3 rearranged patient cohort. To confirm if these additional aberrations are truly TLX3 specific, we analyzed whether these additional abnormalities were also identified in a large-scale T-ALL array-CGH study (n ¼ 85, unpublished data) of non-TLX3 rearranged T-ALL patients (Table 1) . Other known T-ALLspecific genetic aberrations were determined using an RT-PCR or PCR and sequencing strategy or using FISH, and included NOTCH1 mutations, 24 NUP214-ABL1 amplifications 4 and p15/p16 deletions (Supplementary Table 1 ).
The cryptic deletion, del(5)(q35), is associated with TLX3 expression in T-ALL
The most frequent recurrent genetic abnormality identified in TLX3 rearranged cases was a heterozygous deletion at band 5q35, which was present in 5 of 21 (24%) TLX3 rearranged T-ALL cases. The deletional area differed in size among cases. In three cases (nos. 2112, 2640 and 2650), the deletion started just downstream of the TLX3 gene, as shown by the normal hybridization pattern of the TLX3 probe, and loss of all four array-CGH probes covering the nucleophosmin (NPM1) gene located 80 kb telomeric of TLX3 (Figures 1a and b) . For these cases, FISH analysis using the TLX3-U/TLX3-D translocation probes (Supplementary Figure 1) confirmed the presence of this cryptic deletion (Figure 1c ). In the other two cases (nos. 9012 and 222), the deletion started upstream of NKX2-5 (Figures 1d  and e) . However, gene expression array data revealed no NKX2-5 expression in any of these five cases (data not shown). For cases nos. 2112, 2640, 2650 and 9012, the deletion seemed to include the complete telomeric region (Figure 1e ). For case no. 222, the terminal breakpoint was situated downstream of the NSD1 gene. Therefore, the minimal deleted region at 5q35 for these five cases is about 4 Mb in size and contains 30 known genes including the NSD1 gene. Gene expression array data revealed no difference in NSD1 expression levels between del(5)(q35) positive and negative T-ALL patients (data not shown).
Quantitative PCR analysis of the NSD1 gene, which is present in the minimal deleted region, on 26 TLX3 rearranged T-ALL cases and 27 TLX3 negative cases (including TAL1 rearranged, LMO2 rearranged, TLX1 rearranged and CALM-AF10 positive cases), confirmed a one-copy NSD1 loss in all TLX3 rearranged T-ALL cases having the cryptic del(5)(q35) deletion (Figure 1f) . None of the non-TLX3 rearranged cases showed loss of NSD1, indicating that none of these had a similar del(5)(q35).
Next, we studied whether the deletions that started just downstream of the TLX3 gene (nos. 2112, 2640 and 2650), truly represented cryptic 5q35 deletions or rather corresponded to unbalanced TLX3 translocations. Therefore, we performed FISH analysis using BAC clones covering the RANBP17/TLX3 breakpoint region and the telomeric end of chromosome 5 (Supplementary Figure 2A) . For case 2650, FISH analysis, using RP11-1072I20 and RP11-10N18, revealed two fusion signals indicating that both TLX3 gene copies were normally present ( Supplementary Figure 2A,B) . In addition, FISH analysis using RP11-1072I20, RP11-117L6 and CTD-2243O22 confirmed the presence of a del(5)(q35.1q35.3) (Supplementary Figure 2A,B) . In contrast, FISH analysis on case 2640 (Supplementary Figure  2C) revealed an additional RP11-1072I20 (RANBP17/TLX3) hybridization signal, indicative for a cryptic unbalanced chromosomal rearrangement involving the RANBP17/TLX3 loci. FISH analysis for the known translocation partners TCRa/d, TCRb and BCL11B showed that these loci were not involved in this chromosomal rearrangement (Supplementary Figure 2C) , indicating that patient 2640 has a novel variant of TLX3 rearrangement with subsequent loss of 5q35.1. For case 2112, no material was left to perform additional TLX3-specific FISH analyses.
Other recurrent genomic deletions in TLX3 rearranged T-ALL Besides, the cryptic deletion, del(5)(q35), four other recurrent genetic abnormalities were identified in various TLX3 rearranged T-ALL cases (Table 1 and Supplementary Table 1) . At chromosome 1, an identical cryptic deletion of B1 Mb was detected at chromosomal band 1p36 in three cases (nos. 2738, 2112 and 585) (Supplementary Figure 3A) . This deletion area was also comprised in a larger deletion in case no. 2757 that in addition demonstrated multiple deletions on chromosome 1p (Table 1 , Supplementary Figure 3A) . The minimal deleted area on 1p36 for these four cases comprised 18 genes, including HES2, HES3 and chromodomain helicase DNA binding domain 5 (CHD5) (Supplementary Figure 3B) . The centromeric breakpoints of the del(1)(p36.31) in cases nos. 2738, 2112 and 585 all clustered in the CAMTA1 gene (Supplementary Figure 3A) .
Cryptic deletions of chromosome 13q were identified in 2 TLX3 rearranged T-ALL cases (nos. 2112 and 2723, Supplementary Figure 3C ). These deletions differed in size and the minimal deleted region contained the microRNA cluster, miR-15/miR-16a (Supplementary Figure 3D) .
Three T-ALL cases showed cryptic deletions at chromosomal band 16q22.1 (nos. 2100, 2112 and 9012) ( Supplementary  Figure 4A, 
Genetic abnormalities identified in single TLX3 rearranged T-ALL cases
Apart from the recurrent abnormalities, other genetic abnormalities were observed in single cases (Table 1 and Supplementary Table 1 ) and occasionally contained known tumor suppressor genes (FBWX7, WT1, ATM, p27KIP1, NF1). None of these abnormalities have been reported as normal copy number variation in the healthy population. 22 One case (no. 2786) showed a cryptic deletion on the long arm of chromosome 4 of about 2.5 Mb in size, Genetic lesions in TLX3 pediatric T-ALL P Van Vlierberghe et al del(4)(q31.3q32.1), which contained among others the FBXW7 gene ( Figure 2 ). The loss of one FBXW7 gene copy in this case was confirmed using FISH (Figure 2b ). FBXW7 mutations have recently been identified in 8-30% of primary T-ALL samples.
25-28 Therefore, we screened case no. 2786 for the currently known FBXW7 mutations. This analysis revealed no additional FBXW7 mutation on the remaining allele of this case.
Other rearrangements identified in single TLX3 rearranged cases included a cryptic deletion, del(12)(p13.1p13.2), including the CDKN1B/p27/KIP1 gene (no. 9858) and a cryptic deletion, del(17)(q12), including the NF1 gene (no. 2780). 29 In one case (no. 2100), the breakpoint of a cryptic deletion on chromosome 9, del(9)(p24.1p24.2), was situated in JAK2. In another case (no. 1179), the breakpoint of a cryptic deletion on chromosome 11, del(11)(q21q22.3), was located in the ATM gene.
WT1 inactivation in pediatric T-ALL
Another abnormality that was identified in a single TLX3 rearranged case (no. 2723) was a cryptic deletion of about 1.5 Mb in size, del(11)(p13p13), and included the WT1 gene (Figure 3a) . Because conflicting data have been reported on the role of WT1 as a tumor suppressor and/or oncogene in human leukemias, 30 we wondered whether WT1 was indeed the target gene of this genomic deletion. The telomeric breakpoint of this deletion was situated downstream of the WT1 gene, whereas the centromeric breakpoint was located downstream of the CD59 gene (Figure 3a) . FISH analysis confirmed the one-copy loss of WT1 in this case (Figure 3b ). To investigate WT1 inactivation in this case, the remaining WT1 allele was analyzed for the presence of inactivation mutations. A small frameshift mutation (delCinsTAG) was identified in exon 7, disrupting the WT1 coding region (Figure 3c ).
To investigate whether WT1 inactivation is restricted to TLX3 rearranged T-ALL cases, we performed additional WT1-specific FISH analysis on 25 TLX3 negative pediatric T-ALL cases. This revealed one additional case in which FISH analysis revealed a loss of both WT1 gene copies (Figure 3d ). Subsequent array-CGH analysis confirmed the presence of a large monoallelic deletion on the short arm of chromosome 11, del(11)(p13p14.3), in combination with a loss of the genomic region surrounding the WT1 gene on the other allele (Figure 3e ). Gene expression array data showed that WT1 expression was virtually absent in this T-ALL case showing a homozygous WT1 deletion (Supplementary Figure 5 ). For case no. 2723, WT1 was equally expressed compared to WT1 wild-type cases of all T-ALL subgroups (TAL1, LMO2, TLX3, TLX1 and unknown) (Supplementary Figure 5 ).
Discussion
To get more insight in new genetic defects that may cooperate with TLX3 gene expression in the leukemic transformation of thymocytes, we performed array-CGH analysis on a TLX3 rearranged T-ALL patient cohort.
About 25% of TLX3 rearranged T-ALL cases showed a deletion at the terminal end of the long arm of chromosome 5. Interestingly, for a number of cases, the genomic breakpoint of this deletion was situated just downstream of the TLX3 oncogene. The deletions in these cases differ from the previously described TLX3 deletions that involved a genomic region upstream of the TLX3 gene near the translocation breakpoint. 16 Although most T-ALL cases that show TLX3 expression harbor a cryptic translocation at this genomic locus, a number of studies have reported TLX3 activation in the presence of a seemingly normal TLX3 locus. 18, 19 For case no. 2650, combined array-CGH and FISH analysis strongly suggest that the TLX3 expression is associated with a interstitial del(5)(q35.1q35.3) in the absence of a TLX3 translocation. It is therefore tempting to speculate that TLX3 is normally under transcriptional control of a negative regulatory domain downstream of TLX3. Deletion of this negative regulatory element may lead to ectopic TLX3 expression. In addition, a potential tumor suppressor gene could be present in the minimal deleted area at 5q35 that specifically cooperates with TLX3 expression in the leukemogenesis of T-ALL. This hypothesis is strengthened by the fact that two cases have smaller 5q35 deletions with breakpoints near NKX2-5. A potential candidate gene in this 5q35 genomic region is NSD1. Mutations or deletions of the NSD1 gene are the major cause of Sotos syndrome, a constitutional overgrowth disorder, 31 and patients with this syndrome have a higher risk for the development of leukemia. [32] [33] [34] In addition, NSD1 is involved in a cryptic translocation, t(5;11)(q35;p15.5), generating a NUP98-NSD1 fusion gene in acute myeloid leukemia (AML). 35 Although gene expression array data revealed no difference in NSD1 gene expression between patients with and without the del(5)(q35), a future mutation screening of NSD1 in TLX3 rearranged T-ALL is mandatory to evaluate a potential role for NSD1 inactivation in T-ALL.
Cryptic deletions on chromosome 1 were identified in four T-ALL cases with a commonly deleted region surrounding Genetic lesions in TLX3 pediatric T-ALL P Van Vlierberghe et al chromosomal band 1p36. Similar 1p36 deletions were previously identified in about 30% of human neuroblastomas,
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25% of colorectal cancer cases, 37 and a variety of hematological malignancies including AML, 38 chronic myelogenous leukemia 39 and non-Hodgkin's lymphoma. 40 In neuroblastoma and colorectal cancer, reduced expression levels of the CAMTA1 gene correlated with adverse outcome, suggesting that CAMTA1 could act as the 1p36-specifc tumor suppressor gene in these malignancies. 36, 37 Another interesting target gene in this genomic region is the CHD5 gene, which has been shown to be a tumor suppressor that controls proliferation and apoptosis via the p19Arf/p53 pathway. 41 Other potential target genes within this genomic region are HES2 and HES3, both of which are highly similar to HES1 that is a basic helix-loop-helix transcriptional repressor and known NOTCH1 target gene. 42 Also the TNFRSF25 gene may represent a target gene of this deletion. TNFRSF25 is a member of the tumor necrosis factorreceptor family which controls lymphocyte proliferation and regulates cell apoptosis. 43 The minimal deleted region of the cryptic deletions on chromosome 13 contained the microRNA cluster, miR-15/ miR-16a. In chronic lymphocytic leukemia, deletion of this miR-15/miR-16a cluster leads to the activation of antiapoptotic BCL2. 44 For example, in case no. 2723 (Supplementary Table 1 ), activation of BCL2 could cooperate with a homozygous deletion of the p15/p16 locus, a NOTCH1 mutation and activated TLX3 expression in the development of T-ALL.
Three TLX3 rearranged T-ALL cases showed cryptic deletions on chromosomal band 16q22.1. In AML, this genomic region is recurrently targeted by cytogenetic abnormalities including an inversion, inv(16)(p13q22); a translocation, t(16;16)(p13q22) and a deletion, del (16)(q22). 40 The inv(16) and t(16;16) both result in a CBFB-MYH11 fusion gene, which is associated with a more favorable prognosis. 45 In contrast, the deletion del(16)(q22) does not provide a favorable outcome and it remains to be elucidated whether CBFB is targeted in the 16q deletions in AML. 46 In the TLX3 rearranged T-ALL cases, the minimal deleted region on 16q22.1 contained 21 genes but lacked the CBFB gene. One interesting candidate genes in this genomic region is CTCF, which is a conserved transcriptional repressor of the MYC oncogene. 47 MYC has been described in T-ALL to become aberrantly activated due to a TCR-mediated translocation 48 and has been shown to represent an important downstream target of activated NOTCH1. 49, 50 Therefore, inactivation of CTCF could represent an alternative mechanism for MYC activation in T-ALL.
The majority of novel regions of genomic amplification or deletion were only detected in single TLX3 rearranged T-ALL cases (n ¼ 19). Given their low frequency, one could argue that their oncogenic role in T-ALL is negligible. However, NOTCH1, which was originally identified due to its involvement in a rare chromosomal translocation (o1%), was later identified as the most predominant mutational target in T-ALL (450% of cases). 9 Similarly, the cryptic deletion, del(4)(q31.3q32.1), that was detected in a single case, includes the FBXW7 gene. FBXW7 is an F-box protein that binds specific substrates including CyclinE, NOTCH1, cMYC and cJUN target these for ubiquitin-mediated proteolysis. Heterozygous missense mutations of the FBXW7 gene are present in 8-30% of T-ALL cases, [25] [26] [27] [28] demonstrating the importance of this gene in T-ALL albeit inactivation through chromosomal deletions is rare. Mutant FBXW7 has lost the potential to bind the PEST domain of NOTCH1-IC and target NOTCH1 for proteolytic degradation. This results in stabilized NOTCH1-IC in the nucleus, providing an alternative mechanism of NOTCH1 activation in T-ALL that is insensitive for g-secretase inhibition. The present study describes the first case of a heterozygous FBXW7 deletion in human T-ALL. Haploinsufficiency of FBXW7 may be sufficient for NOTCH1 stabilization as no FBXW7 mutation could be identified in the remaining allele. FBXW7 mutations can occur in combination with NOTCH1 heterodimerization (HD) mutations but not with PEST truncating mutations, and may complement the relatively weak transcriptional activity of HD mutant NOTCH1 molecules. 28 In our del(4)(q31.3q32.1)-positive T-ALL case, an activating NOTCH1 mutation was identified in the HD domain.
Deletions on the short arm of chromosome 12 are frequently detected in a wide range of hematological malignancies. A recent genome-wide copy number analysis showed 12p deletions in about 25% of B-ALL cases and suggested the TEL gene as the main target of this genomic abnormality. 51 However, the 12p deletion that we identified was about 600 kb in size and included the CDKN1B/p27/KIP1 gene and the microRNA genes, miR-613 and miR-614, whereas it did not include the TEL gene. This indicates that the target gene(s) for 12p deletions probably differs between T-and B-cells ALL. The CDKN1B/p27/KIP1 gene encodes a cell cycle regulator that, similar to p15/p16, inhibits cyclin-dependent kinases (CDK). Loss of these CDK inhibitors may result in uncontrolled cell cycle. The T-ALL case with this CDKN1B deletion (no. 9858) also contained a homozygous p15/p16 deletion, indicating that different T-cell cycle defects can collaborate with a NOTCH1 mutation and TLX3 overexpression in the development of T-ALL (Supplementary Table 1 ).
WT1, a transcription factor involved in normal cellular development and cell survival, was initially discovered as a tumor suppressor in Wilms' tumor, a pediatric kidney malignancy. 52 In acute leukemias, there is evidence that this gene can both act as an oncogene as well as a tumor suppressor gene. 30 WT1 mutations have been described in AML, leading to a truncated WT1 protein. 53, 54 In addition, specific AML subtypes show low levels of WT1 expression. 30 Both observations are consistent with a tumor suppressor role of WT1 in AML. In contrast, a variety of leukemias are characterized by activated WT1 expression compared to normal bone marrow or normal progenitor cells 55, 56 that has been associated with poor outcome. 57, 58 Our single T-ALL case with a deletion of WT1 combined with an inactivational mutation in the remaining WT1 allele points toward a potential tumor suppressor role of WT1 in T-ALL. WT1 inactivation is not restricted to TLX3 rearranged T-ALL cases, as biallelic WT1 deletions were also observed in a TLX3 negative T-ALL case indicating that WT1 inactivation may be a more general collaborating genetic event in T-cell leukemia. Nevertheless, the TLX3 rearranged T-ALL case showing WT1 inactivation also harbored a miR-15/miR-16a deletion, further extending the range of different genetic defects that collaborate in T-ALL development.
In conclusion, we performed a genome-wide copy number screening on TLX3 rearranged T-ALL cases and identified the cryptic deletion, del(5)(q35), as a new and recurrent genetic aberration that is exclusively associated with TLX3 expression in T-ALL. In addition, we identified a number of genetic events, including FBXW7 and WT1 inactivation that could collaborate with TLX3 expression, NOTCH1 activation and p15/p16 deletion in the development of T-cell leukemia. As shown for FBXW7, the identification of new genomic deletions/amplifications, even at low frequency, can still highlight important target genes with a broader role in T-ALL. Therefore, it is likely that the current overview of genetic defects will be further helpful for a better understanding of the molecular pathways leading to T-cell leukemia.
